Pentoxifylline Treatment in Acute Pancreatitis (AP)

• Status: Completed
• Trial end date: 2017-10-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Pentoxifylline

Criteria

Inclusion criteria

• Enrollment within 72 hours of diagnosis of acute pancreatitis (AP)

• Ability to give informed consent or a Legal Adult Representative (LAR) able to give informed consent for subject when needed as defined buy LAR use guidelines.

• Adult subjects of age ≥18 years.

Exclusion Criteria:

• Moderate or severe congestive heart failure

• History of seizure disorders or demyelinating disease

• Nursing mothers

• Pregnancy

• History of prior tuberculosis or risk factors for tuberculosis

• Evidence of non- corticosteroid immunosuppression (such as malignancy, chronic renal failure, chemotherapy within 60 days, and HIV)

• Evidence of active hemorrhage

• Paralytic ileus with severe nausea and vomiting